Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Justice Department Gives Go-Ahead To CVS, Aetna Deal

Written by: | news@biospace.com | Dated: Friday, July 13th, 2018

 

Justice Department Gives CVS and Aetna Deal a Go-Ahead

 

By Mark Terry

 

The U.S. Justice Department announced yesterday that it will not challenge the merger of CVS Health Corp and health insurer Aetna.

The deal was originally announced on December 3, 2017. CVS plans to buy Aetna for $69 million. Many industry watchers and investors were concerned the Justice Department would challenge the deal the way it has AT&T’s acquisition of Time Warner.

CNBC reports that CVS shares climbed almost three percent at the news, with Aetna stock increasing two percent. It also seemed to have a positive effect on CIGNA and Express Scripts, whose stock both rose. Cigna is currently acquiring Express Scripts.

The Hill believes there are three likely efficiencies that will come out of the merger. The first is a decrease in the cost of clinical care and emergency room visits. The second is improved care coordination for patients. And the third is an increase in the customer base for the CVS MinuteClinic system.

The Hill notes that emergency rooms are the default option for many patients that need unexpected non-emergency care, which is one of the more expensive ways of getting health care. The Hill writes, “For many such immediate health-care needs, local retail clinics providing basic services on a walk-in basis are an alternative source of quality care at a cost vastly lower than possible for emergency rooms. That is a clear benefit of the Aetna/CVS merger: Aetna can cover treatment for non-emergency health-care needs much more effectively and at a lower cost by promoting the CVS walk-in clinics.”

Furthermore, The Hill’s analysis believes that Aetna’s presence in CVS stores will “yield additional benefits for patients attempting to navigate multiple clinic and pharmacy options, with referrals to primary-care physicians when needed.”

Despite The Hill’s focus on the MinuteClinics, Aetna’s chief executive officer Mark Bertolini in a May talk at The Wall Street Journal Health Forum in Washington, DC, said, “Forget the MinuteClinic. It’s not about the MinuteClinic. It’s really about a place in the store where you can come in” and have personalized healthcare solutions offered.

Either way, it’s not really clear if the merger will really improve anything for anybody other than shareholders. Shortly after Bertolini’s talk, Paul Markovich, chief executive officer of Blue Shield of California, indicated that “Industry mergers and acquisitions don’t always live up to their ambitions because ‘your strategy quickly becomes paying off your bankers, especially when you’re a publicly traded company,’” reported MarketWatch.

In June, it was reported that several Aetna executives would take on management positions at the combined company. Aetna President Karen Lynch will be president of the Aetna business unit, as well as an executive vice president of CVS. Shawn Guertin, Aetna’s chief financial officer and chief enterprise risk officer, will be executive vice president and chief financial officer of CVS. David Denton, CVS’ current chief financial officer, will leave the company. Fran Soistman, executive vice president and head of government services at Aetna, will continue with the merged company. Richard di Benedetto will stay as president of Aetna International. Rick Jelinek, head of enterprise strategy at Aetna, will be executive vice president of CVS. Aetna’s chief medical officer, Harold Paz, indicates he will stay on “for a period of time” to help with the transition.

 

 

BioSpace source:

https://www.biospace.com/article/justice-department-gives-cvs-and-aetna-deal-a-go-ahead

 

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom